Results 11 to 20 of about 134,499 (99)

Comparaison des mécanismes de cytotoxicité des anticorps monoclonaux anti-CD20 Rituximab et GA101 dans les cellules fraiches de la Leucémie Lymphoïde Chronique

open access: yes, 2010
CD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro.
Reslan, Lina
core   +4 more sources

Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells

open access: yes, 2017
Rituximab (RTX) has been the hallmark anti-CD20 mAb for the treatment of B cell neoplasms, including B cell chronic lymphocytic leukemia (B-CLL). Recently, a novel humanized anti-CD20 mAb obinutuzumab (GA101) has been implemented as first-line CLL ...
William F. C. Rigby   +4 more
core   +1 more source

Supplementary Figure 2 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

open access: yes, 2013
PDF file - 307K, Whole-blood B-cell depletion mediated by GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) in lepirudin-treated (A, B) and heat-inactivated (HI) (C) whole-blood samples.
Michael Weidner (15065545)   +21 more
core   +1 more source

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

open access: yes, 2011
We analyzed in B-chronic lymphocytic leukemia (B-CLL) whole blood assays the activity of therapeutic mAbs alemtuzumab, rituximab, and type II glycoengineered anti-CD20 mAb GA101.
Martino Introna   +6 more
core   +1 more source

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

open access: yes, 2011
Sensitivity of chronic lymphocytic leukemia (CLL) cells to anti-CD20 mAbs is low and, therefore, the efficacy of monotherapy with current anti-CD20 mAbs is limited. At present, it is not known whether sensitivity of CLL cells to CD20 mAbs is modulated by
Gregor G. W. van Bochove   +9 more
core   +1 more source

Therapy optimization of aggressive non-Hodgkin's lymphoma: Preclinical evaluation of GA101

open access: yes, 2012
Antikörperabhängige zellvermittelte Zytotoxizität (ADCC) ist einer der Hauptwirk-mechanismen monoklonaler anti-CD20-Antikörper bei der Elimination maligner B-Zell-Lymphome. Trotz moderner Immunchemotherapien gibt es Therapieversager.
Schroer, Hinrich   +6 more
core   +1 more source

Darko Šiško, PhD in Technical Sciences

open access: yesKartografija i Geoinformacije, 2018
On 29 October 2018, Darko Šiško defended his doctoral dissertation Geoinformation Land Use Model as a Basis for Urban Area Strategic Planning at the Faculty of Architecture of the University of Zagreb.
Tihomir Jukić, Vlado Cetl
doaj  

23rd Congress of the European Hematology Association Stockholm, Sweden, June 14‐17, 2018

open access: yes, 2018
HemaSphere, Volume 2, Issue S1, Page 1-1113, June 2018.
wiley   +1 more source

Home - About - Disclaimer - Privacy